GLP-1R/GIPR Interactions in Central Energy Balance and Implications for Obesity Pharmacotherapy
- 1Department of Biochemistry and Molecular Biology, College of Life Sciences, Nanjing Forestry University, Nanjing 210037, China
- 2ZhenCui (Jiangsu) Enzyme Technology Development Co., Ltd., Shuyang 223600, China
Abstract
GLP-1R/GIPR agonists have emerged as the dominant pharmacological strategy for obesity, producing unprecedented weight loss. Yet why patients respond so differently to treatment remains a persistent clinical puzzle. GLP-1R agonists produce body weight reductions of up to 15–17% in clinical trials, and dual GIP/GLP-1R agonists push this further to 20–25%; despite this, the central neural mechanisms underlying this gap remain incompletely understood. This Review integrates preclinical and clinical evidence in the hypothalamic and brainstem circuits that govern energy homeostasis, with a particular focus on GLP-1R and GIPR signaling in the GABAergic neurons that co-express both receptors in the arcuate nucleus and nucleus tractus solitarius. In these neurons, the two receptors pull in opposite directions on excitability by regulating ion channels differently. GLP-1R activation hyperpolarizes the neurons and reduces GABA release, while GIPR activation promotes firing and restores GABAergic tone. Genetic deletion of GIPR in GABAergic neurons enhances GLP-1R agonist efficacy in male mice, indicating that GIPR signaling constrains GLP-1R action within this defined neuronal population. This local constraint does not generalize to GIPR biology as a whole. Dual agonists outperform GLP-1R monotherapy clinically; GIPR signaling in the median eminence oligodendrocytes enhances GLP-1R agonist brain access, and both GIPR agonism and antagonism can reduce body weight through distinct mechanisms. We propose a cell-type-resolved framework that reconciles these findings, state testable predictions that follow from it, and highlight the gaps in sex, species and human data. We conclude that no clinically validated strategy yet takes advantage of the GIPR/GLP-1R interaction, which leaves a major gap in precision obesity pharmacotherapy.
Related
- Sphingolipid signatures at the extremes of energy balance: a comparative study of obesity and anorexia nervosa in women
- Navigating the Biomolecular Corona: Biological Interactions and Therapeutic Implications of RNA–Lipid Nanoparticles
- Abdominal Obesity, Brain Glymphatic Function, and LH–dlHPC Appetite Regulation: Current Evidence, Potential Links, and Implications for Metabolic Health
- Epigenetic Rewiring of Enhancer–Promoter Interactions in Cancer: Mechanisms and Therapeutic Implications
- Viral-Gut Microbiota Interactions: Implications for the Gut Mucosa in Inflammatory Bowel Disease.
BibTeX
@article{hamza2026glp1rgipr,
title = {{GLP-1R/GIPR Interactions in Central Energy Balance and Implications for Obesity Pharmacotherapy}},
author = {Amir Hamza and Nisha Farooq and Xunyong Zhou and Su Bu},
journal = {Biomolecules},
year = {2026},
month = nov,
doi = {10.3390/biom16111623},
url = {https://www.mdpi.com/2218-273X/16/11/1623},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - GLP-1R/GIPR Interactions in Central Energy Balance and Implications for Obesity Pharmacotherapy
AU - Amir Hamza
AU - Nisha Farooq
AU - Xunyong Zhou
AU - Su Bu
PY - 2026
DA - 2026/11/07
JO - Biomolecules
DO - 10.3390/biom16111623
UR - https://www.mdpi.com/2218-273X/16/11/1623
AB - GLP-1R/GIPR agonists have emerged as the dominant pharmacological strategy for obesity, producing unprecedented weight loss. Yet why patients respond so differently to treatment remains a persistent clinical puzzle. GLP-1R agonists produce body weight reductions of up to 15–17% in clinical trials, and dual GIP/GLP-1R agonists push this further to 20–25%; despite this, the central neural mechanisms underlying this gap remain incompletely understood. This Review integrates preclinical and clinical evidence in the hypothalamic and brainstem circuits that govern energy homeostasis, with a particular focus on GLP-1R and GIPR signaling in the GABAergic neurons that co-express both receptors in the arcuate nucleus and nucleus tractus solitarius. In these neurons, the two receptors pull in opposite directions on excitability by regulating ion channels differently. GLP-1R activation hyperpolarizes the neurons and reduces GABA release, while GIPR activation promotes firing and restores GABAergic tone. Genetic deletion of GIPR in GABAergic neurons enhances GLP-1R agonist efficacy in male mice, indicating that GIPR signaling constrains GLP-1R action within this defined neuronal population. This local constraint does not generalize to GIPR biology as a whole. Dual agonists outperform GLP-1R monotherapy clinically; GIPR signaling in the median eminence oligodendrocytes enhances GLP-1R agonist brain access, and both GIPR agonism and antagonism can reduce body weight through distinct mechanisms. We propose a cell-type-resolved framework that reconciles these findings, state testable predictions that follow from it, and highlight the gaps in sex, species and human data. We conclude that no clinically validated strategy yet takes advantage of the GIPR/GLP-1R interaction, which leaves a major gap in precision obesity pharmacotherapy.
SN - 2218-273X
ER -